Skip to main content
. 2022 Jul 14;11(14):4080. doi: 10.3390/jcm11144080

Figure 2.

Figure 2

A suggest algorithm to managing dyslipidemia in transplant patients. Atorva: atorvastatin; AZA: azathioprine; CsA: cyclosporine; CVD: cardiovascular diseases; Eze: ezetimibe; Fluva: fluvastatin; o.d.: once daily; LDL: low-density lipoprotein; MMF: mycophenolate mofetil; mTORi: mammalian target of rapamycin inhibitors; PCSK9: Proprotein convertase subtilisin/kexin 9; Prava: pravastatin; Rosuva: rosuvastatin (* should be avoided severe chronic kidney disease); Tac: tacrolimus. Yellow color: low-intensity statin, expected LDL circulating reduction <30%; Orange color: moderate-intensity statin, expected LDL circulating reduction 30–50%; Red color: high-intensity statin or PCSK9i, expected LDL circulating reduction >50%; Color gradient for Eze indicates differences in LDL circulating reduction if ezetimibe is administered alone or co-administered with statin.